News
Explore the latest stories and publications from NCATS and our partners, see upcoming events, or explore the variety of resources we provide to better understand translational science and our work.
News
Read the latest news from NCATS and its collaborators whose research is supported through the Center’s programs, or follow coverage of NCATS' translational research activities through national and local media.
NIH Awards $15M+ to Baylor-Led Consortia Targeting Rare Bone and Metabolic Disorders
September 27, 2025 - Media Coverage
- Rare Diseases Clinical Research Network (RDCRN)
NIH Awards More Than $15 Million to Fund Two Rare Diseases Consortia
September 25, 2025 - Grantee/Partner News
- Rare Diseases Clinical Research Network (RDCRN)
Propelling Cures With Genetics Research: Interview With Joni L. Rutter, PhD, Director of the National Center for Advancing Translational Sciences at NIH
December 14, 2023 - Grantee/Partner News
- 3-D Tissue Bioprinting
- Bespoke Gene Therapy Consortium (BGTC)
- Clinical and Translational Science Awards (CTSA) Program
- New Therapeutic Uses (NTU)
- Platform Vector Gene Therapy (PaVe-GT)
- Rare Diseases Clinical Research Network (RDCRN)
- Somatic Cell Genome Editing (SCGE)
- Therapeutics for Rare and Neglected Diseases (TRND)
- Tissue Chip for Drug Screening
Newborn Screening for Rare Immune Disorders Led to Earlier Treatment, Improved Survival
November 20, 2023 - NCATS News
- Rare Diseases Clinical Research Network (RDCRN)
An NCATS-led Rare Diseases Clinical Research Network consortium changed what is known about severe combined immunodeficiency. Researchers developed lifesaving therapies for the disease and pioneered a screening test for newborns.
Forgoing One Food Treats Eosinophilic Esophagitis as Well as Excluding Six
February 27, 2023 - NCATS News
- Rare Diseases Clinical Research Network (RDCRN)
Consortium in Action: Scientists Lay a Foundation for New Drug
December 3, 2020 - NCATS News
- Rare Diseases Clinical Research Network (RDCRN)
Years of NIH-supported studies contributed to the U.S. Food and Drug Administration approval of a new drug for acute intermittent porphyria—a rare, debilitating condition. The NCATS-supported Porphyrias Consortium played a pivotal role in its development.